A cervical cancer vaccine from GlaxoSmithKline (GSK) prevents lesions, the FDA found as it...


A cervical cancer vaccine from GlaxoSmithKline (GSK) prevents lesions, the FDA found as it considers an end-of-month approval of the first competitor to Merck's (MRK) Gardasil. More miscarriages were reported with the GSK drug, Cervarix, though the FDA says the data "do not establish a causal relationship."

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs